Brind.

Waters Corporation partners to expand CDx and flow cytometry capabilities in Jining

1 report, 1 independent Updated Mon 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Waters Corporation established a strategic partnership to jointly pursue companion diagnostic (CDx) and next-generation flow cytometry opportunities with pharmaceutical and biotechnology companies. The collaboration aims to provide sponsors with a coordinated path from biomarker strategy through clinical development and global commercialization. The partnership leverages the CAP-accredited laboratory capabilities in Jining, China.

From selectscience.net

Why it matters

Some supportBrind's analysis of the reports

The collaboration combines Waters Corporation's underlying technology, including instrumentation and reagents, with expertise in biomarker and clinical development. Together, the companies aim to deliver standardized and globally scalable solutions for precision medicine.

From selectscience.net

Who's involved

  • Waters CorporationProvides underlying technology capabilities, including instrumentation, reagents, standardized panels, and software analysis.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped